The Good Bug Secures Rs 100 Crore in Funding for Gut Health Innovation

Gut health startup The Good Bug has successfully raised Rs 100 crore (approximately $12 million) in a Series B funding round, led by Susquehanna Asia Venture Capital, the venture capital branch of Susquehanna International Group. Existing investor Fireside Ventures also contributed to this funding round.

Previously, the Mumbai-based startup raised $4 million in a Series A extension in 2024, which was spearheaded by Sharrp Ventures, the family office of Harsh Mariwala from the Marico Group. This latest funding round elevates The Good Bug’s total capital to nearly $20 million.

The funds will be allocated to enhance research and development in microbiome science, scale up clinical trials, expand distribution channels, and elevate brand awareness among both consumers and healthcare professionals, as stated by The Good Bug in their press release.

Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, The Good Bug focuses on creating probiotic and gut-oriented health products aimed at improving digestion, immunity, and metabolic health. Recently, the startup launched Metabolically Lean, a GLP-1-based formula positioned as a natural and non-invasive alternative to weight-loss medications such as Ozempic and Mounjaro. The brand asserts that the product effectively elevates GLP-1 levels, helping to reduce appetite and enhance metabolism.

Keshav Biyani, co-founder of The Good Bug, expressed, “The primary use of these funds will concentrate on fostering innovation in microbiome science and bacterial research. The startup will continue to invest in clinical trials, brand development, and the recruitment of exceptional talent in research, science, and business.”